- INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in slowing IPF disease progression through 96…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
Information contained on this page is provided by an independent third-party content provider.
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
Information contained on this page is provided by an independent third-party content provider.
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
SOURCE Boehringer Ingelheim Pharmaceuticals - INPULSIS®-ON extension study demonstrated the efficacy of Ofev® (nintedanib) in…
RIDGEFIELD, Conn., Oct. 23, 2017 /PRNewswire/ -- Boehringer Ingelheim announced today the presentation of a new analysis on the…
RIDGEFIELD, Conn., Oct. 23, 2017 /PRNewswire/ -- Boehringer Ingelheim announced today the presentation of a new analysis on the…
RIDGEFIELD, Conn. Results from an open-label extension of the Phase III INPULSIS® trial, known as INPULSIS®-ON, suggest Ofev is…
La mitad recibe en primera instancia un diagnóstico erróneo. Antes de llegar al correcto, la mayoría consulta a más de un médico.
I risultati dello studio INJOURNEY che ha valutato nintedanib in associazione a pirfenidone come terapia della fibrosi…
I risultati dello studio INJOURNEY che ha valutato nintedanib in associazione a pirfenidone come terapia della fibrosi…
A combination of Boehringer Ingelheim‘s Ofev (nintedanib) and Genentech’s Esbriet (pirfenidone) as a treatment for idiopathic…
Data from this 12-week study show that the safety and tolerability profile of nintedanib with add-on pirfenidone is in keeping…
I risultati dello studio INJOURNEYTM che ha valutato nintedanib in associazione a pirfenidone come terapia della fibrosi…
I risultati dello studio INJOURNEYTM che ha valutato nintedanib in associazione a pirfenidone come terapia della fibrosi…
RIDGEFIELD, Conn., Sept. 11, 2017 /PRNewswire/ -- Results from the INJOURNEY ™ trial, investigating the use of Ofev ® (nintedanib…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
Information contained on this page is provided by an independent third-party content provider.
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
Information contained on this page is provided by an independent third-party content provider.
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
RIDGEFIELD, Conn., Sept. 11, 2017 /PRNewswire/ -- Results from the INJOURNEY™ trial, investigating the use of Ofev® (nintedanib…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…
SOURCE Boehringer Ingelheim Pharmaceuticals - Data from this 12-week study showed that the safety and tolerability profile of…